The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Hi, good afternoon. Thanks for taking the question. So, yeah, as you said, the quarter really demonstrated how diverse your different revenue
streams are. The one that grew this quarter in particular was the distributed. Revenue segment, I guess with the launch of the new product, the
new biosimilar product, was there one time sales in the quarter or, how should we view this distribution channel called forward.
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Okay, so there was no, stocking or channel filling in the quarter. These were, you think, these types of numbers you think will be, going forward.
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Okay, and then a similar question on the SG&A expense. I mean down pretty significantly from the year over -- down significantly year over year,
were there one time things -- there that helped that or do you think you'll stay around these levels?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 13, 2025 / 12:30PM, KMDA.OQ - Q2 2025 Kamada Ltd Earnings Call
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Okay. And then last question for me, something I asked, three months ago, you said the tax rate would, continue to be a little bit lumpy in in 2025.
You know what was responsible for the tax credit in the June quarter and where do you think the tax rate will be in September and December?
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Okay, so when those [KOLs] are used up, as you look into 2026 and beyond, what do you think will be an effective tax rate?
|
